Abstract
Background. A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test.
Investigations. Physical examination, pregnancy test, echocardiography.
Diagnosis. Unintended pregnancy during adjuvant trastuzumab therapy.
Management. Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Azim, H. & Azim, H. A. Jr Targeting Her-2/neu in breast cancer: as easy as this! Oncology 74, 150–157 (2008).
Berkowitz, G. S., Skovron, M. L., Lapinski, R. H. & Berkowitz, R. L. Delayed child-bearing and the outcome of pregnancy. N. Engl. J. Med. 322, 659–664 (1990).
Koren, G., Pastuszak, A. & Ito, S. Drugs in pregnancy. N. Engl. J. Med. 338, 1128–1137 (1998).
Leyland-Jones, B. Dose-scheduling—Herceptin. Oncology 61 (Suppl. 2), 31–36 (2001).
Watson, W. J. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet. Gynecol. 105, 642–643 (2005).
Fanale, M. A., Uyei, A. R., Theriault, R. L., Adam, K. & Thompson, R. A. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin. Breast Cancer 6, 354–356 (2005).
Waterston, A. M. & Graham, J. Effect of adjuvant trastuzumab on pregnancy. J. Clin. Oncol. 24, 321–322 (2006).
Bader, A. A., Schlembach, D., Tamussino, K. F., Pristauz, G. & Petru, E. Anhydramnios associated with adminstration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 8, 79–81 (2007).
Shrim, A., Garcia-Bournissen, F., Maxwell, C., Farine, D. & Koren, G. Favorable pregnancy outcome following Trastuzumab (Herceptin®) use during pregnancy. Case report and updated literature review. Reprod. Toxicol. 23, 611–613 (2007).
Sekar, R. & Stone, P. R. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet. Gynecol. 110, 507–510 (2007).
Witzel I. D., Müller, V., Harps, E., Janicke, F. & Dewit, M. Trastuzumab is pregnancy associated with poor fetal outcome. Ann. Oncol. 19, 191–192 (2008).
Berveiller, P., Mir, O., Sauvanet, E., Antoine, E. C. & Goldwasser, F. Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod. Toxicol. 25, 286–288 (2008).
Pant, S., Landon, M. B., Blumenfeld, M., Farrar, W. & Shapiro, C. L. Treatment of breast cancer with trastuzumab during pregnancy. J. Clin. Oncol. 26, 1567–1569 (2008).
Weber-Schoendorfer, C. & Schaefer, C. Trastuzumab exposure during pregnancy. Reprod. Toxicol. 25, 390–391 (2008).
Perez, E. A. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin. Breast Cancer 8 (Suppl. 3), S114–S120 (2008).
Sliwa, K., Fett, J. & Elkayam, U. Peripartum cardiomyopathy. Lancet 368, 687–693 (2006).
Negro, A., Brar, B. K. & Lee, K. F. Essential roles of Her2/erbB2 is cardiac development and function. Recent Prog. Horm. Res. 59, 1–12 (2004).
Acknowledgements
H. A. Azim, Jr and F. A. Peccatori contributed equally to this work. H. A. Azim, Jr was supported by a European School of Oncology (ESO) fellowship.
Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. Goldhirsch receives research support from Roche. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Azim, H., Peccatori, F., Liptrott, S. et al. Breast cancer and pregnancy: how safe is trastuzumab?. Nat Rev Clin Oncol 6, 367–370 (2009). https://doi.org/10.1038/nrclinonc.2009.48
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.48
This article is cited by
-
Trastuzumab administration during pregnancy: an update
BMC Cancer (2021)
-
Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis
BMC Women's Health (2021)
-
Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case–control study
Breast Cancer Research and Treatment (2021)
-
Reproductive outcomes following treatment for a gynecological cancer diagnosis: a systematic review
Journal of Cancer Survivorship (2019)
-
Trastuzumab administration during pregnancy: a systematic review and meta-analysis
Breast Cancer Research and Treatment (2013)